Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06087328 · ClinicalTrials.gov registry record · Phase 2
CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes
A Phase 2 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 2
- Development phase
- 46
- Enrollment target
NCT06087328 is a Phase 2 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 46 participants.
The verdict
NCT06087328, a Phase 2 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 46 participants
- Enrollment target
Study Summary
Many people smoke cigarettes and use e-cigarettes, and have a hard time stopping. Nicotine replacement therapy medications, such as nicotine patches and lozenges, have been shown to help people quit e-cigarette use. The purpose of the present study is to see how well nicotine patches and lozenges help people quit both smoking and vaping, and to determine if higher doses of the medication work best.
Interventions
- DRUG Regular Nicotine patch and lozenge dose
- DRUG Augmented Nicotine patch and lozenge dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2024-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06087328
The ClinicalTrials.gov registry entry for NCT06087328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Regular Nicotine patch and lozenge dose is the first listed.
NCT06087328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06087328 about?
NCT06087328 is a clinical study titled "CAN-DOSE Study: Cessation With Augmented Nicotine for Dual Use Of Smoking and E-cigarettes". Many people smoke cigarettes and use e-cigarettes, and have a hard time stopping. Nicotine replacement therapy medications, such as nicotine patches and lozenges, have been shown to help people quit e-cigarette use. The purpose of the present study is to see how well nicotine patches and lozenges he...
What is the current status of trial NCT06087328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2023-12-05. Estimated completion is 2024-11-05.
What interventions are being tested in trial NCT06087328?
The interventions under investigation include: Regular Nicotine patch and lozenge dose (DRUG), Augmented Nicotine patch and lozenge dose (DRUG).
Who is sponsoring clinical trial NCT06087328?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.